ArticleJCEM case reports2026
A disappearing diabetes: extreme and reversible hyperglycemia during an ulcerative colitis flare.
Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stress hyperglycemia commonly occurs during acute illness; however, extreme hyperglycemia accompanied by markedly elevated glycated hemoglobin (HbA1c) in individuals without pre-existing diabetes is rare and may mimic new-onset diabetes. We describe a 56-year-old man with no prior history of diabetes who presented with severe diarrhea, abdominal pain, and weight loss and was found to have profound hyperglycemia, 603 mg/dL (SI: 33.5 mmol/L) (reference range, 70-99 mg/dL [SI: 3.9-5.5 mmol/L]), without metabolic acidosis. HbA1c was markedly elevated at 9.4% (reference range, 4.0%-5.7%), despite a normal value documented 2 months earlier. Evaluation demonstrated preserved endogenous insulin secretion, elevated homeostatic model assessment of insulin resistance, and negative autoimmune markers. Imaging excluded pancreatic pathology, while colonoscopy and histopathology confirmed active moderate ulcerative colitis (UC). The patient was treated with intravenous corticosteroids and insulin therapy, with rapid normalization of glycemia allowing discontinuation of insulin. Sustained euglycemia was observed after remission, with HbA1c normalizing to 4.7% at 3-month follow-up. This case highlights that severe inflammation during an UC flare can induce profound yet reversible hyperglycemia, emphasizing the need for careful interpretation and longitudinal follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.